Back to VSTMView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
23 competitors in COVID-19
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA5/19/2021
Copiktra
Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
DefactinibPhase 3
Pancreatic Adenocarcinoma
avutometinibPhase 3
Low Grade Serous Ovarian Cancer
avutometinib (VS-6766)Phase 2
Low Grade Ovarian Serous Adenocarcinoma
Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2
Low Grade Serous Ovarian Cancer
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2
KRAS Activating Mutation
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts